Chemical structure:

IUPAC name:

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

CAS number:

960404-48-2

Therapy area:

Anti-diabetic

References:

IH/USP

Status:

Under development

Mechanism of action

In patients with type 2 diabetes mellitus (T2DM), it is an orally active, highly selective SGLT2 inhibitor that enhances glycemic control by lowering renal glucose reabsorption, which results in urine glucose excretion (glucuresis). Dapagliflozin, when taken orally, is quickly absorbed and often reaches its peak plasma concentrations within two hours.

DISCLAIMER: PRODUCTS COVERED BY VALID & UNEXPIRED PATENTS ARE NOT OFFERED (OR) SUPPLIED FOR COMMERCIAL SCALE. THE PATENT POSITION SHOULD BE VERIFIED & LIABILITY LIES WITH THE CUSTOMER ONLY. PRODUCTS COVERED BY PATENTS ARE AVAILABLE ONLY FOR R&D USE.